BCPT

(redirected from Breast Cancer Prevention Trial)
Also found in: Acronyms.

BCPT

Breast Cancer Prevention Trial. A study of 13388 women at increased risk of breast cancer (BC): in women age 60+, < age 60 but at increased risk of BC, or with history of lobular carcinoma in situ, and randomised to receive tamoxifen or placebo.

Results
Tamoxifen reduces the risk of invasive BC by 49%; despite its side effects—e.g., increased risk of endometrial cancer, RR 2.53, stroke, pulmonary embolism and deep vein thrombosis—its use as a prophylaxis is appropriate in high-risk women.
References in periodicals archive ?
The initial results of the breast cancer prevention trial were released in 1998, showing a 45 percent reduction in breast cancer among the high-risk participants who took tamoxifen.
Wickerham said, adding that the findings of the current study don't contradict those of the Breast Cancer Prevention Trial.
NCI has temporarily halted recruitment of patients into the breast cancer prevention trial, which, like B-14, is run by NSABP.
For example, this case has raised questions about the Breast Cancer Prevention Trial, a controversial study in which healthy women at high risk of developing breast cancer take the drug tamoxifen in hopes of staving off the disease (SN: 4/16/94, p.
The Breast Cancer Prevention Trial involving over 13,000 women proved that healthy women at high risk for developing breast cancer can reduce their risk by 44% with Nolvadex(R).
The Gail model was validated in the breast Cancer Prevention Trial of the National Surgical Adjuvant Breast and Bowel Project, sponsored by the National Cancer Institute.
The Breast Cancer Prevention Trial (BCPT), completed in 1998, demonstrated that the drug tamoxifen lowered the risk of breast cancer by 50% in high-risk women.
The carefully worded document reviews the results of the large Breast Cancer Prevention Trial (P-1), which showed that high-risk women taking tamoxifen had a 49% decrease in the incidence of breast cancer.
In NCI's ongoing breast cancer prevention trial, "98 percent of the participants aren't going to benefit from tamoxifen, yet fall 8,000 healthy women slated to receive it] will be at risk for the adverse outcomes.
Tamoxifen was shown to reduce the chance of developing breast cancer by about half in the Breast Cancer Prevention Trial (BCPT), a recently completed study of over 13,000 premenopausal and postmenopausal women at high risk for breast cancer.
The magnitude of risk reduction is similar to that seen in the Breast Cancer Prevention Trial among women on tamoxifen who had three or more first-degree relatives with breast cancer, she said.
Full browser ?